4G/5G polymorphism modulates PAI-1 circulating levels in obese women

Mol Cell Biochem. 2012 May;364(1-2):299-301. doi: 10.1007/s11010-012-1230-1. Epub 2012 Jan 19.

Abstract

The increase in plasminogen activator inhibitor type 1 (PAI-1) has been described as a risk factor to thrombosis-related diseases. In addition, it has been demonstrated that the variant 4G of polymorphism 4G/5G located in promoter region of PAI-1 gene is associated with higher PAI-1 levels. We investigate the role of this polymorphism on circulating PAI-1 concentration in a population of 57 obese women (23%, 4G/4G; 49%, 4G/5G and 28%, 5G/5G genotypes). Our results demonstrate a genotype-specific modulation on PAI-1 levels in obese women, thus 5G/5G genotype presented significantly lower levels of plasma PAI-1 when compared to 4G/4G group (46 ± 19 ng/mL vs. 63 ± 13 ng/mL, respectively). Our findings indicate that obese carriers of 4G/4G genotype may have increased risk to develop thrombotic diseases.

MeSH terms

  • Adult
  • Body Mass Index
  • Female
  • Gene Frequency
  • Genotype
  • Heterozygote
  • Humans
  • Obesity / blood*
  • Obesity / complications
  • Obesity / genetics*
  • Plasminogen Activator Inhibitor 1 / blood*
  • Plasminogen Activator Inhibitor 1 / genetics*
  • Polymorphism, Genetic*
  • Promoter Regions, Genetic
  • Risk Factors
  • Venous Thrombosis / complications
  • Venous Thrombosis / genetics

Substances

  • Plasminogen Activator Inhibitor 1